23 November 2018 - Sublocade is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of moderate to severe opioid use disorder.

Indivior today announced that Health Canada has approved Sublocade (buprenorphine extended-release) injection for subcutaneous use, for the management of moderate to severe opioid use disorder in adult patients who have been inducted and clinically stabilised on a transmucosal buprenorphine containing product. Sublocade should be used as part of a complete treatment plan that includes counselling and psychosocial support, and must only be administered once a month, subcutaneously in the abdominal region by a healthcare provider. 

In Canada, Sublocade will be marketed by Indivior Canada and will be available by the second half of 2019.

Read Indivior press release